Review
Chemistry, Multidisciplinary
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Davood Bashash
Summary: This review provides an overview of the current research status of immune checkpoint blockades in breast cancer and discusses the efficacy and limitations of ICB therapy in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Review
Oncology
Carly C. Barron, Isabella Stefanova, Yevin Cha, Karam Elsolh, Arman Zereshkian, Nessma Gaafour, Elaine McWhirter
Summary: Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents. Little is known about chronic irAEs and they are felt to be rare.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou
Summary: A nanocarrier that achieves self-blockade of PD-L1 in tumor cells and a detection kit to quantitatively measure the binding rate of PD-1/PD-L1 have been developed, improving the efficacy of PD-1/PD-L1 self-blocking therapy.
ADVANCED MATERIALS
(2022)
Article
Oncology
Jing Yang, Shilin Zhao, Jing Wang, Quanhu Sheng, Qi Liu, Yu Shyr
Summary: Cancer-Immu is a comprehensive platform that integrates various omics data and clinical phenotypes to explore immunogenomic connections. It provides easy access to data and helps researchers translate omics datasets into biological insights and clinical applications.
Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Kavita M. Dhodapkar, Alyssa Duffy, Madhav V. Dhodapkar
Summary: Blocking immune checkpoints has revolutionized cancer therapy, but immune-related adverse events (irAEs) pose a challenge to its clinical application. B cells, known players in autoimmunity, have been targeted successfully for autoimmune disorders. While T cells have been extensively studied in immune checkpoint blockade (ICB), these checkpoints also affect B cell tolerance. This review focuses on the role of humoral immunity, specifically B cell subsets and autoantibodies, in the pathogenesis of ICB-induced irAEs. Understanding T:B cell cross talk may uncover new targets or strategies to prevent or treat irAEs and improve ICB therapy in cancer.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Immunology
Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
Summary: The CD24 protein is expressed on the surface of various normal cells and plays a significant role in tumor development. It facilitates tumor cell proliferation, metastasis, immune evasion, and induces drug resistance. Targeting CD24 has shown significant anti-tumor effects and may represent an effective strategy for treating malignant tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt
Summary: Checkpoint inhibitors (CPIs) disrupt immune checkpoint molecules to block regulatory immune signals, but can cause immune-related adverse events (irAEs) similar to autoimmune diseases. Understanding irAE pathobiology may lead to targeted mitigation strategies and predictive biomarkers. This review focuses on irAEs in the gut, skin, and synovial joints, comparing them to immune-mediated diseases. Studies show dysregulation of cytokines, T-cell infiltration, and potential therapeutic opportunities for irAEs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H. Johnson, Chrystia M. Zobniw, Van A. Trinh, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M. Elsayes, Kaysia Ludford, Emma J. Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A. Sparks, Osama Abu-Shawer, Osama Rahma, Uma Thanarajasingam, Ashley M. Zeman, Rafee Talukder, Namrata Singh, Sarah H. Chung, Petros Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey Weber, Jean H. Tayar, Maria E. Suarez-Almazor, Noha Abdel-Wahab, Adi Diab
Summary: This retrospective study evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) therapy for immune-related adverse events (irAEs). The results showed that anti-IL-6R treatment can improve irAEs without hindering antitumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
You-Zhe Lin, Shu-Hsuan Liu, Wan-Rong Wu, Yi-Chun Shen, Yuan-Liang Wang, Chien-Ching Liao, Pei-Le Lin, Han Chang, Liang-Chih Liu, Wei-Chung Cheng, Shao-Chun Wang
Summary: This study identifies miR-4759 as a novel non-coding RNA that enhances anti-tumor immune response in breast cancer by targeting the PD-L1 gene. In patients with breast cancer, downregulation of miR-4759 is associated with poor prognosis.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Oncology
Marina Chiara Garassino, Antoni Ribas
Summary: The immunomodulatory effects of immune-checkpoint blockade therapy for cancer may affect the immune response to COVID-19, particularly in severe cases. Current evidence does not support the idea that this therapy worsens COVID-19 complications, allowing for its continued use during the pandemic while collecting data on its effects on COVID-19 vaccination.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Biochemical Research Methods
Weibin Huang, Yuhui Zhangt, Songyao Chent, Haofan Yin, Guangyao Liu, Huaqi Zhang, Jiannan Xu, Jishang Yu, Yujian Xia, Yulong He, Changhua Zhang
Summary: In this study, a gene expression profile (PIAM) representing the infiltration of multiple immune cell types and a profile (PIDG) indicating immune cell dysfunction were identified in gastric cancer. A computational framework (GSClassifier) was developed to predict the response to immune checkpoint inhibitors. The PAD-II subtype showed the highest objective response rate, while PAD-I, PAD-III, and PAD-IV subtypes had lower response rates.
BRIEFINGS IN BIOINFORMATICS
(2023)
Article
Biochemical Research Methods
Weibin Huang, Yuhui Zhang, Songyao Chen, Haofan Yin, Guangyao Liu, Huaqi Zhang, Jiannan Xu, Jishang Yu, Yujian Xia, Yulong He, Changhua Zhang
Summary: This study identified four immune subtypes in gastric cancer patients using Pan-Immune Activation Module and Pan-Immune Dysfunction Genes, and developed a highly accurate model for predicting response to ICI therapy. The PAD-II subtype showed the highest objective response rate among the subtypes.
BRIEFINGS IN BIOINFORMATICS
(2022)